Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics ( (AU:ENP) ) has issued an update.
Entropy Neurodynamics Limited reported that all resolutions put to shareholders at its Extraordinary General Meeting in Melbourne on 19 March 2026 were passed by the required majorities. The outcomes, detailed in official voting results, reinforce board-backed proposals and provide governance continuity as the company advances its psilocin-based psychedelic therapy programs.
The company highlighted prior Phase 2a trials using oral psilocybin in binge eating disorder, irritable bowel syndrome, and fibromyalgia, which demonstrated clinical benefits that will inform further development of TRP-8803. By securing shareholder support and building on positive trial data, Entropy aims to strengthen its position in the emerging psychedelic-assisted psychotherapy market and progress toward a more scalable, commercially feasible treatment model.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited is a clinical-stage biotechnology company focused on developing proprietary formulations of psilocin administered with psychotherapy to address diseases with unmet medical needs. Its lead program, TRP-8803, is an intravenous psilocin formulation designed to improve on oral psilocybin by speeding onset, better controlling the psychedelic experience, and shortening treatment duration to a commercially viable timeframe.
Average Trading Volume: 2,357,804
Technical Sentiment Signal: Sell
Current Market Cap: A$53.37M
For an in-depth examination of ENP stock, go to TipRanks’ Overview page.